1. Amidon GL, Lennemäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vitro bioavailability. Pharm Res. 1995;12(3):413–20.
2. Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Bethesda, MD; Aug 2000 (updated May 2015).
3. Papadopoulou V, Valsami G, Dokoumetzidis A, Macheras P. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. Int J Pharm. 2008;361(1–2):70–7.
4. Guideline on the investigation of bioequivalence. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). London, England; 2010.
5. WHO Technical Report Series, No. 937. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. World Health Organization (WHO). Geneva, Switzerland; 2006.